Intermediate rectal dose is associated with late toxicity after prostate SBRT: a dose–volume histogram principal component analysis
Clinical and Translational Oncology · 03.08.2026
DOI: 10.1007/s12094-026-04522-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 03.08.2026. Verfasst von Amadeo J Wals Zurita und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Hospital Universitario Virgen Macarena, Seville, Spain. amadeoj.wals.sspa@juntadeandalucia.es. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
To evaluate whether principal component analysis (PCA) of rectal and bladder dose–volume histograms (DVHs) identifies dose regions associated with late toxicity after prostate stereotactic body radiotherapy (SBRT). Methods/patients This retrospective single-institution study included 106 patients with linked clinical and dosimetric data after prostate SBRT to 36.25 Gy in five fractions. PCA was applied separately to whole-organ and wall-based rectal and bladder DVHs. Associations with late grade ≥ 2 gastrointestinal (GI) and genitourinary (GU) toxicity at 12 months were explored using Spearman correlation, ROC analysis and deliberately limited logistic regression. Toxicity was extracted retrospectively from institutional follow-up records scored according to CTCAE v5.0.
Results
Among 84 patients with 12-month follow-up in the DVH-linked dosimetric cohort, grade ≥ 2 toxicity was uncommon, with 3 GI events (3.6%) and 2 GU events (2.4%). Intermediate-dose rectal metrics showed the strongest exploratory signal for late GI toxicity, particularly rectal V18.1 Gy (AUC 0.868, 95% CI 0.740–0.997) and V29 Gy (AUC 0.827). These estimates are based on very few events and should not be interpreted as validated predictive performance or as evidence of a new planning threshold. No bladder or bladder-wall metric showed clinically meaningful discrimination for GU toxicity.
Conclusions
Intermediate whole-rectum dose was associated with late GI toxicity in this low-event SBRT cohort, but the findings are exploratory and require validation. No isolated dosimetric predictor of late GU toxicity was identified.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Hospital Universitario Virgen Macarena, Seville, Spain. amadeoj.wals.sspa@juntadeandalucia.es.
- Department of Radiation Oncology, Hospital Universitario Virgen Macarena, Seville, Spain.
- Department of Medical Physics, Hospital Universitario Virgen Macarena, Seville, Spain.
Zitieren
APA
Zurita, A. J. W., Vacas, A. I., Del Río, H. M., Jiménez, M. R., Ruíz, P. V., Bejarano, J. S., Ureña, A., Seidel, M. O., & Peña, F. C. (2026). Intermediate rectal dose is associated with late toxicity after prostate SBRT: a dose–volume histogram principal component analysis. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04522-2
Vancouver
Zurita AJW, Vacas AI, Del Río HM, Jiménez MR, Ruíz PV, Bejarano JS, et al. Intermediate rectal dose is associated with late toxicity after prostate SBRT: a dose–volume histogram principal component analysis. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04522-2
BibTeX
@article{Zurita2026,
author = {Zurita, Amadeo J Wals and Vacas, Ana Illescas and Del Río, Héctor Miras and Jiménez, María Rubio and Ruíz, Paula Vicente and Bejarano, Jonathan Saavedra and Ureña, Antonio and Seidel, Mónica Ortiz and Peña, Francisco Carrasco},
title = {Intermediate rectal dose is associated with late toxicity after prostate SBRT: a dose–volume histogram principal component analysis},
journal = {Clinical and Translational Oncology},
year = {2026},
doi = {10.1007/s12094-026-04522-2}
}
EUVIMED